The American Journal of Managed Care22h
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...
STAT21h
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
Dermatology Advisor37m
Skin Cancer Risk Increases With Age Among People Living With HIV
Older adults with HIV are at significantly higher risk for cutaneous malignancies when compared with younger patients with HIV.
Immune response may be harnessed to control HIV, primary trial results suggest
Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...
Healio18h
‘We have come a long way’: Empirical data support UNAIDS HIV incidence estimates
HIV incidence in sub-Saharan Africa has declined substantially, according to both UNAIDS estimates and empirical data pulled ...
Measles is unlike other viruses: What to know about complications including 'immune amnesia'
It’s not yet known how many people have gotten sick in the Texas measles outbreak, but there are at least 215 confirmed cases ...
Uganda Business News16h
Trump’s foreign aid cuts will cripple Africa’s HIV/AIDS response
US funding to fight HIV/AIDS has saved 26 million lives since 2003, with the greatest benefits felt in sub-Saharan Africa ...
KFF Health News2h
Gilead’s HIV Drug Prevents Infection With One Shot A Year Instead Of Two
The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...